Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal Journal of Islamic Pharmacy Pharmaceutical Journal of Indonesia Hubungan Tingkat Pengetahuan Petugas Pengelola Obat dengan Tingkat Ketersediaan Obat Di Puskesmas Kota Malang
Medina, Farah
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Diabetes Caused by Statin Use: A Review Zulfiana, Risa; Medina, Farah; Suharjono, Suharjono
Journal of Islamic Pharmacy Vol 5, No 1 (2020): J. Islamic Pharm.
Publisher : Universitas Islam Negeri Maulana Malik Ibrahim Malang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18860/jip.v5i1.8652

Abstract

Statins are generally recognised as being safe and well tolerated cholesterol-lowering drug and have been successfully used for prevention of primary and secondary cardiovascular disease. However, Some researchers have reported diabetes development in patients taking statins. A number of meta-analyses conducted in recent years have proved that the association is real even though its causality have not been fully elucidated. Various pathophysiological mechanisms that could explain the increased risk of diabetes in patients treated with statin have been described. These are mainly responsible for impairment of β -cell insulin secretion and alteration of intercellular signaling through depletion of important downstream products.  This review aims to examine the relationship between statin treatment and the presence of diabetes. Previous clinical reviews of the evidence and pathophysiological mechanisms involved may also be explained. Furthermore, many studies have concluded that Pitavastatin and pravastatinom do not affect glycemic control and may be a beneficial treatment option in patients with, or at risk for, type 2 diabetes.
ALIROCUMAB : MECHANISM OF ACTION, PHARMACOKINETICS, SAFETY, AND CLINICAL OUTCOMES Medina, Farah; -, Sumarno
Pharmaceutical Journal of Indonesia Vol 5, No 1 (2019)
Publisher : Brawijaya University

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Hyperlipidemia is an established risk factor for developing cardiovascular disease (CVD). The latest guideline on lipid management emphasize treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) at doses proven to reduce CVD events.  However, some of statin-treated patients have persistently elevated cardiovascular risk due to inadequate lowering of low density lipoprotein cholesterol (LDL-C) levels. In addition, adverse effects of statins may limit their tolerability and therefore the ability to attain effective doses in some patients. A new class of drugs that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) has been developed to treat hyperlipidemia.  PCSK9 inhibitors are monoclonal antibodies for proprotein convertase-subtilicin/kexin type 9 which significantly reduces the concentration of LDL-C in vivo by inhibiting the degradation of LDL receptors in hepatocytes. The introduction of the PCSK9 inhibitor was heralded a new era of intensive LDL-C reductions with LDL-C concentrations lowered below the rate that once thought possible with conventional treatments such as statins. On July 24, 2015, the United States Food and Drug Administration (FDA) approved Alirocumab, the first converged proprotein of the Subtilisin Kexin 9 (PCSK9) inhibitor. This review discusses the mechanisms of action, pharmacokinetics, safety and clinical outcomes of the Alirocumab.
ALIROCUMAB : MECHANISM OF ACTION, PHARMACOKINETICS, SAFETY, AND CLINICAL OUTCOMES Medina, Farah; -, Sumarno
Pharmaceutical Journal of Indonesia Vol 5, No 1 (2019)
Publisher : Brawijaya University

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Hyperlipidemia is an established risk factor for developing cardiovascular disease (CVD). The latest guideline on lipid management emphasize treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) at doses proven to reduce CVD events.  However, some of statin-treated patients have persistently elevated cardiovascular risk due to inadequate lowering of low density lipoprotein cholesterol (LDL-C) levels. In addition, adverse effects of statins may limit their tolerability and therefore the ability to attain effective doses in some patients. A new class of drugs that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) has been developed to treat hyperlipidemia.  PCSK9 inhibitors are monoclonal antibodies for proprotein convertase-subtilicin/kexin type 9 which significantly reduces the concentration of LDL-C in vivo by inhibiting the degradation of LDL receptors in hepatocytes. The introduction of the PCSK9 inhibitor was heralded a new era of intensive LDL-C reductions with LDL-C concentrations lowered below the rate that once thought possible with conventional treatments such as statins. On July 24, 2015, the United States Food and Drug Administration (FDA) approved Alirocumab, the first converged proprotein of the Subtilisin Kexin 9 (PCSK9) inhibitor. This review discusses the mechanisms of action, pharmacokinetics, safety and clinical outcomes of the Alirocumab.
Co-Authors Suharjono, Suharjono SUMARNO Zulfiana, Risa